ArticleNature2020
A genomic and epigenomic atlas of prostate cancer in Asian populations.
Abstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 241 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
241citing papers in PubMed, 2 pooled it
27.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
241 citing papers in PubMed, 2 syntheses or guidelines pooled it, 346 citations in OpenAlex.
- Neurovascular structure-adjacent frozen-section examination vs. standard robot-assisted radical prostatectomy: a systematic review and meta-analysis of two-arm comparative studies on functional and oncological outcomes.Journal of robotic surgery · 2025Pooled it
- The association between diabetes mellitus and prostate cancer: a meta-analysis and Mendelian randomization.Aging · 2024Pooled it
- Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.Cell reports. Medicine · 2025Trial
- The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.Nature communications · 2026Article
- Single-cell and spatial RNA sequencing in prostate cancer.Nature reviews. Urology · 2026Review
- Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives.International journal of molecular sciences · 2026Review
- Real-world effectiveness and safety of radium-223 therapy in castration-resistant prostate cancer with bone metastases.Asian journal of andrology · 2026Article
- Origins and consequences of oncogenic 3D chromatin remodelling.Nature reviews. Cancer · 2026Review
- Multi-omics dissection of FOXA1 reveals cancer-type-specific transcriptional networks and functional risk variants.iScience · 2026Article
- Urinary DNA Methylation Profiling Improves Discrimination of Prostate Cancer Across PSA-Defined Risk Strata.Biochemical genetics · 2026Article
- Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer.Cancer metastasis reviews · 2026Review
- PDIA1 promotes androgen receptor activation and prostate cancer cell survival through enhancing HMMR stability.FEBS letters · 2026Article
- Integrating DNA methylation and clinical features to predict prostate cancer prognosis.BMC cancer · 2026Article
- EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer.The Journal of clinical investigation · 2026Article
- The significance of urine extracellular vesicle DNA methylation detection in the diagnosis and classification of prostate cancer.Journal of advanced research · 2026Article
- CCDC78 is required for prostate cancer cell growth and serves as a prognostic biomarker for high-risk disease.Discover oncology · 2026Article
- GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST).BJU international · 2026Article
- Single base focal hypermutation cooccurs with structural variation as an early event in advanced prostate tumourigenesis with ancestry specific independence: a multi-ancestral observational study.Genome medicine · 2026Observational
- Aberrant activation of epigenetic BRD9-DGAT1 axis promotes lipid droplets deposition and ferroptosis resistance in YAP-high prostate cancer.Cell death & disease · 2026Article
181 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors at 15 institutions in 2 countries.
Jing Li *Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Chuanliang Xu *Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Hyung Joo Lee *Department of Genetics, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-7030-5390
Shancheng RenDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Xiaoyuan ZiDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.ORCID http://orcid.org/0000-0002-2374-9001
Zhiming ZhangNovogene Co, Ltd, Beijing, China.
Haifeng WangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Yongwei YuDepartment of Pathology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Chenghua YangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Xiaofeng GaoDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Jianguo HouDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Linhui WangDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Bo YangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Qing YangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Huamao YeDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Tie ZhouDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Xin LuDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Yan WangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Min QuDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Qingsong YangDepartment of Radiology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Wenhui ZhangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Nakul M ShahDepartment of Genetics, Washington University School of Medicine, St Louis, MO, USA.
Erica C PehrssonDepartment of Genetics, Washington University School of Medicine, St Louis, MO, USA.
Shuo WangDepartment of Urology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Zengjun WangState Key Laboratory of Reproductive Medicine and Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jun JiangDepartment of Urology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China.ORCID http://orcid.org/0000-0001-9408-2972
Yan ZhuDepartment of Pathology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Rui ChenDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Huan ChenDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Feng ZhuDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Bijun LianDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Xiaoyun LiNovogene Co, Ltd, Beijing, China.
Yun ZhangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Chao WangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.ORCID http://orcid.org/0000-0002-0812-904X
Yue WangShanghai Key Laboratory of Cell Engineering, Shanghai, China.
Guangan XiaoDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Junfeng JiangShanghai Key Laboratory of Cell Engineering, Shanghai, China.
Yue YangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Chaozhao LiangDepartment of Urology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Jianquan HouDepartment of Urology, First Affiliated Hospital of Soochow University, Suzhou, China.
Conghui HanDepartment of Urology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China.
Ming ChenDepartment of Urology, Zhongda Hospital, Southeast University, Nanjing, China.
Ning JiangDepartment of Urology, Gongli Hospital, Second Military Medical University, Shanghai, China.
Dahong ZhangDepartment of Urology, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.
Song WuDepartment of Urology Institute of Shenzhen University, Shenzhen Luohu People's Hospital, Shenzhen, China.
Jinjian YangDepartment of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Tao WangDepartment of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yongliang ChenDepartment of Urology, Shaoxing Central Hospital, Shaoxing, China.
Jiantong CaiDepartment of Urology, Shishi Hospital, Shishi, China.
Wenzeng YangDepartment of Urology, The Affiliated Hospital of Hebei University, Baoding, China.
Jun XuDepartment of Urology, Huadong Hospital, Fudan University, Shanghai, China.
Shaogang WangDepartment of Urology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.
Xu GaoDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China. gaoxu.changhai@foxmail.com.
Ting WangDepartment of Genetics, Washington University School of Medicine, St Louis, MO, USA. twang@wustl.edu.ORCID http://orcid.org/0000-0002-6800-242X
Yinghao SunDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China. sunyhsmmu@126.com.
Second Military Medical University · CNWashington University in St. Louis · USArmy Medical University · CNNovogene Bioinformatics Institute · CNTongji Hospital · CNAffiliated Hospital of Hebei University · CNAnhui Medical University · CNFirst Affiliated Hospital of Zhengzhou University · CNFudan University · CNJiangsu Province Hospital · CNShaoxing People's Hospital · CNShenzhen University · CNXuzhou Medical College · CNZhejiang Provincial People's Hospital · CNZhongda Hospital Southeast University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the second most common cancer in men worldwide
Indexed as
Epigenesis, GeneticEpigenomicsGenomicsMutationAsian PeopleCarrier ProteinsCell Transformation, NeoplasticChinaCohort StudiesDNA-Binding ProteinsDNA HelicasesDNA MethylationGene Expression Regulation, NeoplasticGenome, HumanHepatocyte Nuclear Factor 3-alphaHumansCarrier ProteinsCHD1 protein, humanDNA-Binding ProteinsDNA HelicasesFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaNerve Tissue ProteinsZNF292 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.